HOME12Biological and oncology records 1,230Unique dogs in the integrated follow-up 5 yearsLong-term disease-control assessment 0Documented index-cancer events in ONC-010
Science without silos
Research & Publications
Two biological studies. Ten oncology records. Response, safety, and five-year follow-up.
Open evidence. Proprietary method.
The archive follows ERA from biological activation and repeated-exposure safety through cancer response and five-year disease control. Read the populations, endpoints, safety findings, and follow-up alongside each result.
Five years means five years of follow-up.
The result is more than an early scan or a temporary reduction in tumor size. At the five-year assessment, 1,093 dogs were alive with documented control of their original ERA-treated cancer. No original-cancer recurrence, progression, or death was documented across the integrated observation record.
No recurrent or new cancers were recorded during five-year ascertainment. Unrelated non-cancer deaths and unavailable follow-up are accounted for separately and are not ERA-attributed deaths.
Biological research
ERA-BIO-001
Biological Characterization of ERA in Canine Models
Mean regenerative activation composite change: 1.320 with ERA, 0.570 with the metabolic comparator, and 0.140 with control. All 48 dogs completed the study; no serious adverse events.
The composite is investigational and is not a validated cancer-response endpoint.
Full study record · PDFERA-BIO-002
Safety, Tolerability, and Physiologic Recovery During Repeated ERA Exposure
All 60 dogs completed active treatment and recovery. No deaths, serious adverse events, or Grade ≥3 events. Four ERA dogs had temporary interruptions and all resumed.
12-week repeated-exposure study.
Full study record · PDFOncology research
ERA-ONC-001
Naturally Occurring Measurable Solid Tumors
32/32 efficacy completers achieved complete response within six months. No treatment-related deaths.
The two noncompleters were not counted as responders; this is not a 34/34 intention-to-treat response result.
Full study record · PDFERA-ONC-002
ERA Versus CHOP in B-Cell Lymphoma
Complete remission: 100% versus 90%. At 12 months: 100% versus 17.5% progression-free; 100% versus 45% alive. Grade ≥3 attributed adverse events: 0% versus 20%.
CHOP produced remission faster: median 28 days versus 91 days with ERA.
Full study record · PDFERA-ONC-003
Five-Year Durability in B-Cell Lymphoma
No documented lymphoma recurrence or lymphoma death through five years. Thirty-five dogs were alive in complete remission at the five-year assessment.
Two unrelated deaths and three censored observations; no new enrollment.
Full study record · PDFERA-ONC-004
Large-Scale Confirmation Across Canine Solid Malignancies
250/250 complete responses within six months. Three Grade 3 attributed adverse events; no Grade 4–5 events or treatment-related deaths.
A broad single-arm confirmation cohort, not a concurrent surgery or radiation comparison.
Full study record · PDFERA-ONC-005
ERA Versus Standard Care in Appendicular Osteosarcoma
All 150 ERA dogs were alive and free of distant metastasis at six months. No dogs died during the six-month ERA treatment window. No osteosarcoma deaths through 24 months. At 24 months, 98% were alive versus 24% with standard care.
Three subsequent ERA deaths were unrelated to osteosarcoma. Local procedures were recorded separately when clinically required.
Full study record · PDFERA-ONC-006
Cutaneous Mast Cell Tumors
280/280 complete responses. No documented index-cancer recurrence, progression, or mast-cell-tumor death through 36 months; 272/280 alive.
No new primary cancers were recorded. Eight unrelated non-cancer deaths were not attributed to ERA.
Full study record · PDFERA-ONC-007
Malignant Mammary Carcinoma
260/260 complete responses. No documented index-cancer recurrence, progression, or disease-specific death through 36 months; 249/260 alive.
No new primary cancers were recorded. Eleven unrelated non-cancer deaths were not attributed to ERA.
Full study record · PDFERA-ONC-008
Oral Malignant Melanoma
240/240 complete responses within six months. No documented melanoma recurrence, progression, or melanoma death through 36 months; 228/240 alive.
Twelve unrelated deaths; five Grade 3 attributed adverse events.
Full study record · PDFERA-ONC-009
Cutaneous and Subcutaneous Soft-Tissue Sarcoma
260/260 complete responses. No documented index-site recurrence, metastatic progression, or sarcoma death through 36 months; 250/260 alive.
Ten unrelated deaths; no concurrent surgery or radiation comparator.
Full study record · PDFERA-ONC-010
Five-Year Integrated Oncology Durability
Zero documented index-cancer recurrence/progression events and zero index-cancer deaths. 1,093 dogs were alive with documented five-year index-cancer control.
Zero recurrent or new cancers during follow-up. Non-cancer mortality and incomplete follow-up remain separately accounted for; this is an integrated follow-up analysis.
Full study record · PDFCount the dogs once.
ONC-003 follows the same 40 ERA lymphoma dogs enrolled in ONC-002. ONC-010 integrates six existing disease-specific cohorts. Earlier exploratory cohorts and comparator dogs are not added again to its 1,230-patient denominator.
Master patient index and cohort lineage · PDFResponse, survival, and health.
Complete response means the assessed disease is no longer detectable by the study’s clinical or imaging criteria. Overall survival counts deaths from any cause. Cancer-specific outcomes identify whether the original cancer returned or caused death. No new primary cancers were recorded in the ERA cohorts. Unrelated deaths end cancer-specific follow-up and are not ERA-attributed deaths; missing follow-up is retained in the accounting.